San Diego, CA, United States
San Diego, CA, United States

Time filter

Source Type

As the exclusive licensee for veterinary applications of this technology, Zander Therapeutics anticipates a crossover effect for canines with cancer and autoimmune disorders.  Because canine DNA is close to human DNA structure, it is believed that advancements by Regen BioPharma will directly impact advancements for Zander Therapeutics in developing small molecule therapies for canine cancer and autoimmune disorders in dogs. The NR2F6 nuclear receptor has been identified as a potentially extremely important immune cell inhibitor and cancer stem cell differentiator.  Molecules which function as immune cell inhibitors are called "immune checkpoints" and basically act as an "on or off switch" to an immune response. Cancer cells sometimes find ways to use these checkpoints to avoid being attacked by the immune system - therefore therapies that target these checkpoints demonstrate tremendous potential as cancer treatments. The NR2F6 program at Zander Therapeutics is focused on identifying antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a dog's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity. "In addition to the data we received on medicinal chemistry optimization, Zander Therapeutics is conducting ex vivo studies using blood samples from dogs.  The Company is examining the validity that because dog DNA and human DNA are so close, any human related advancements made by Regen BioPharma should have a positive impact on our canine model for treating dogs with cancer or autoimmune diseases," says David Koos, Ph.D., Chairman & CEO Zander Therapeutics, Inc. About Zander Therapeutics Inc. and Entest BioMedical Inc.: Zander Therapeutics is a subsidiary of Entest BioMedical Inc. (OTCPink: ENTB), a publicly traded biotechnology company focused on veterinary medicine. The Company seeks to develop small molecule and immune stimulating therapies for veterinary applications. Currently, the Company's major interest is in developing small molecule therapies for treating cancer and autoimmune diseases in animals, which include arthritis. Zander Therapeutics Inc. is the exclusive licensee for veterinary applications of Regen BioPharma Inc.'s (OTCQB: RGBP) (OTCQB: RGBPP) intellectual property and technology relating to NR2F6. NR2F6 is a molecular switch known as a "orphan nuclear receptor", which controls genes associated with the immune response.  Zander Therapeutics is solely focused on veterinary applications. David Koos serves as Chairman and Chief Executive officer of Regen BioPharma, Inc. (OTCQB: RGBP), Entest BioMedical Inc. (OTCPINK: ENTB) and Zander Therapeutics Inc. (subsidiary of Entest BioMedical Inc.). Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Methods of treatment of cancer are disclosed through administration of siRNA and shRNA sequences silencing BORIS gene and isoforms thereof. One embodiment of the invention discloses pharmaceutical compositions and kits for modifying the palliative procedure of transarterial chemoembolization so as to promote uptake of gene silencing inducing agents into the hepatic cancer microenvironment. By selectively administering under localized increased pressure, enhanced uptake of gene silencing agents is achieved, thus increasing targeting of tumor cells, particularly stem cells.

News Article | December 10, 2016

— Aplastic Anemia Pipeline Market Companies Involved in Therapeutics Development are 3SBio Inc, Acceleron Pharma Inc, Amgen Inc, BioLineRx Ltd, F. Hoffmann-La Roche Ltd, Gamida Cell Ltd, Pluristem Therapeutics Inc, and Regen BioPharma Inc. Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia. Symptoms include fatigue, pale skin, rapid or irregular heart rate, shortness of breath with exertion, nosebleeds and bleeding gums, prolonged bleeding from cuts, skin rash, dizziness and headache. Risk factors include exposure to toxic chemicals, treatment with high-dose radiation or chemotherapy for cancer, certain blood diseases, autoimmune disorders and serious infections. Treatment includes immunosuppressants and stem cell transplant. This research provides comprehensive information on the therapeutics under development for Aplastic Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Inquire more about this research at The Aplastic Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Aplastic Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 1, 1 and 5 respectively. Aplastic Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Buy a copy of this research report at • The pipeline guide provides a snapshot of the global therapeutic landscape of Aplastic Anemia (Hematological Disorders). • The pipeline guide reviews pipeline therapeutics for Aplastic Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Aplastic Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Aplastic Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Aplastic Anemia (Hematological Disorders) • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. • Find and recognize significant and varied types of therapeutics under development for Aplastic Anemia (Hematological Disorders). • Classify potential new clients or partners in the target demographic. • Develop tactical initiatives by understanding the focus areas of leading companies. • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. • Formulate corrective measures for pipeline projects by understanding Aplastic Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics. • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. For more information, please visit

SAN DIEGO, March 2, 2017 /PRNewswire/ -- CheckPoint Formed as a Subsidiary of the Company to Simplify any Potential Future Transactions Involving the Company's NR2F6 Technology Regen BioPharma Inc. (OTCQB: RGBP), (OTCQB: RGBPP) has granted CheckPoint Immunology Inc. (a...

The current invention discloses compositions of matter, protocols and methods of screening test compounds to identifying agonists and antagonists of the orphan nuclear receptor NR2F6 by measuring the ability of a test compound to occupy the active site of NR2F6, in the presence of a reference compound.

Regen BioPharma Inc. | Date: 2013-08-02

Disclosed are therapeutic methods for ex-vivo activation of immune cells from a cancer patient for the purpose of inducing tumor regression and/or suppressing metastasis and/or tumor recurrence. In one embodiment mononuclear cells of a patient are isolated from peripheral blood and activated by a combination of innate immune system activators together with means allowing for T cell activation.

Means and compositions of matter are disclosed for stimulation of innate immunity in controlling, substantially reducing, and/or clearing filoviral infections including Margburg and Ebola virus. In one embodiment an activator of dendritic cells (DC) is provided to replicate a state similar to one found in patients that significantly overcome filoviral infections. In one particular embodiment the HMGB1-derived peptide SAFFLFCSE or derivatives thereof are administered in a pharmacologically acceptable formulation. Efficacy may be augmented by administration of agents that increase monocyte numbers, which are thereafter stimulating to differentiate along the DC pathway by filoviral infection, or by administration of flt-3 ligand. Alternatively GM-CSF may be administered. Naturally derived compounds such as plant based lectins are also utilized to stimulate DC maturation through activation of receptors such as toll like receptors (TLR).

The invention discloses novel methods, compositions of matter, and kits for the treatment of disorders affecting the hematopoietic system. Patients are administered an autologous cellular mixture derived from adipose stromal vascular fraction, said cellular mixture comprising endothelial cells, endothelial progenitor cells, T regulatory cells, monocytes, and hematopoietic stem cells. In one embodiment, treatment is provided for patients suffering from inflammatory disorders including aplastic anemia.

Treatment of cancer is disclosed through administration of proteins or specific peptides in vivo, in a matter eliciting monocyte or dendritic cell migration in order to allow uptake of said administrated proteins or peptides, followed by administration of a maturation signal in vivo. The invention provides for treatment of cancer through induction of anticancer immunity and/or immunity towards tumor associated blood vessels.

Compositions useful for treatment of patients needing hematopoietic stimulation. In one embodiment patients are administered a cellular mixture derived from allogeneic placenta, said cellular mixture comprising substantially of endothelial cells and endothelial progenitor cells.

Loading Regen BioPharma Inc. collaborators
Loading Regen BioPharma Inc. collaborators